ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 706,89
0,00%
Dow Jones
39 411,21
0,67%
DAX
18 325,58
0,77%
Brent Oil
85,225
-0,05%
Bitcoin
60 929,76
1,11%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aquestive Therapeutics Inc (AQST)

  7. Aquestive Therapeutics Inc (AQST) Actualités

AQST Aquestive Therapeutics Inc

2,42
-0,14 (-5,47%)
25 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Aquestive Therapeutics Inc AQST NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,14 -5,47% 2,42 01:23:26
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,56 2,41 2,58 2,43 2,56
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/6/202414:00GLOBEAquestive Therapeutics to Join the Russell 3000® and Russell..
12/6/202423:14EDGAR2Form 3/A - Initial statement of beneficial ownership of..
11/6/202418:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202418:35EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/6/202414:13EDGAR2Form 8-K - Current report
06/6/202422:05EDGAR2Form 8-K - Current report
03/6/202414:00GLOBEAquestive Therapeutics Announces Executive Appointments and..
28/5/202414:00GLOBEAquestive Therapeutics to Present Anaphylm™ (epinephrine)..
13/5/202419:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202419:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202414:00GLOBEAquestive Therapeutics to Participate in The Citizens JMP..
07/5/202422:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202422:21EDGAR2Form 8-K - Current report
07/5/202422:19GLOBEAquestive Therapeutics Reports First Quarter 2024 Financial..
29/4/202413:00GLOBEAquestive Therapeutics Receives U.S. FDA Approval and Market..
25/4/202414:00GLOBEAquestive Therapeutics to Report First Quarter 2024..
12/4/202422:01GLOBEAquestive Therapeutics to Present Crossover Study Data for..
01/4/202414:00GLOBEAquestive Therapeutics Strengthens Board of Directors with..
25/3/202413:00GLOBEAquestive Therapeutics Announces Closing of Underwritten..
20/3/202402:49GLOBEAquestive Therapeutics Announces Pricing of $75 Million..
19/3/202421:01GLOBEAquestive Therapeutics Announces Proposed Public Offering of..
14/3/202422:23GLOBEAquestive Therapeutics Announces Pivotal Study for Anaphylm™..
11/3/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:14EDGAR2Form 144 - Report of proposed sale of securities
05/3/202423:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202423:09EDGAR2Form 8-K - Current report
05/3/202423:05GLOBEAquestive Therapeutics Reports Full Year 2023 Financial..
21/2/202414:00GLOBEAquestive Therapeutics to Report Fourth Quarter 2023..
15/2/202414:00GLOBEAquestive Therapeutics to Present Anaphylm™ (epinephrine)..
14/2/202421:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202423:02EDGAR2Form S-8 - Securities to be offered to employees in employee..
30/1/202414:00GLOBEAquestive Therapeutics to Participate in Oppenheimer 34th..
08/12/202316:46EDGAR2Form 8-K - Current report
05/12/202314:51EDGAR2Form 8-K - Current report
05/12/202314:00GLOBEAquestive Therapeutics Doses First Patient in Phase 3..
10/11/202314:00GLOBEAquestive Therapeutics to Present Positive Data from..
08/11/202323:04EDGAR2Form 8-K - Current report
06/11/202323:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202323:20EDGAR2Form 8-K - Current report
06/11/202322:37GLOBEAquestive Therapeutics Reports Third Quarter 2023 Financial..
02/11/202313:45EDGAR2Form 8-K - Current report
02/11/202313:00GLOBEAquestive Therapeutics Completes $45 Million Debt..
31/10/202313:00GLOBEAquestive Therapeutics to Report Third Quarter 2023..
10/10/202318:04EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
AQST
Aquestive Therapeutics
BOV
PINE4M
PINE PN
BIT
P1ZPI9
NLBNPIT1ZPI9 20241220 220
NASDAQ
VWUSX
TG
0XD
Reconnaissance Energy Af...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés